📣 Join the MICROB-PREDICT Consensus Conference in Barcelona (for #EASLCongress attendees only)
📅 27 May 2026
⏰ 15:30 – 18:30 h
Experts will discuss #microbiome mechanisms and biomarkers to improve patient stratification and therapeutic response in #cirrhosis and #ACLF.
@easlnews.bsky.social
Sounds like an exciting conference, Hugh Amsterdam must be beautiful this time of year! Are there any particular sessions you’re most looking forward to at #EASLCongress?
#HepatitisC is a curable disease, but life-saving treatment is priced out of reach for millions of people who need it.
On #WorldHepatitisDay, join us as we call for access to affordable treatments globally!
👉 Read more about the study presented at the 2025 #EASLCongress in May: bit.ly/4fdYoxS
New data presented by Datuk Dr Radzi Abu Hassan at the 2025 #EASLCongress showed that the ravidasvir/sofosbuvir treatment can be safely shortened from 12 to 8 weeks. This shorter regimen is intended for people living with #HepC who do not have cirrhosis.
Link to the poster: dndi.org/wp-content/u...
Help shape #EASLCongress 2026! We’re gathering input from the hepatology community to build a relevant, inclusive, and impactful programme. Share your insights in our short survey + enter to win free registration. 👉 www.surveymonkey.com/r/6F9BRBD
@easlnews.bsky.social Studio during #EASLcongress 2025 in Amsterdam with discussions on therapeutic targets in decompensated #cirrhosis involving @debbieshawcross.bsky.social and representatives of @boehringerglobal.bsky.social and @genfit.bsky.social
✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement.
🗓️ What a fun #workshop at #EASLCongress 2025
Made it home after cycling over 300km en route to #EASLCongress 2025 in Amsterdam, via my hometown, Bruges, Antwerp, and Rotterdam.
Great conference with a particularly interesting session on the considerations when selecting animal models for MASLD!
What a pleasure to meet many friends and colleagues during @easlnews.bsky.social #EASLcongress 2025 in Amsterdam.
A special last minute surprise was Prof. Tung-Hung Su from Taiwan.
The new EASL CPGs on HBV infection have been released yesterday at #EASLCongress What an effort, but what a great journey with an outstanding panel of colleagues! #HBV #Hepatology
@ihuhepatolyon.bsky.social
doi.org/10.1016/j.jh...
🔬 Improving the prognostic performance of the #MELD score is a challenge that Nikolaj Torp (Odense University Hospital) took on, comparing the original score with MELD 3.0 in 777 patients with an acute #decompensation of #cirrhosis
#POSTER SAT-196-YI 👏
📅 Presented at #EASLCongress | #EASL2025
No difference in primary outcome for either dose. Discontinuation due to AE rate was similar across arms #EASLCongress
Late breakers from
#EASLCongress 👇
#EASL2025 #liversky
Of those referred for further work up for chronic liver disease, based on elevated ALT or VCTE, ‘confirmed’ disease prevalence was 32% (greater in those referred due to ALT and VCTE, lower in those referred due to ALT alone) #EASLCongress
In ~30,000 people, prevalence of LSM >=8 kPa was 4.6%, and increased with risk factors. Prevalence in those with 4 risk factors and risky alcohol use was 36% #EASLCongress
Isabel Graupera presents results from the LIVERSCREEN study on the prevalence of liver fibrosis (based on VCTE >=8 kPa) in the general adult European population #EASLCongress
✨ #PosterTour today at #EASLCongress 2025:
All our 3 Horizon2020 #LiverResearch projects in 1 session!
Topic: #Cirrhosis & #PortalHypertension
Chair: Maria Papp
💡 Big moments:
#AMMON-OHE model for post-#TIPS #encephalopathy (Rajiv Jalan)
#Terlipressin response in AKI-HRS w/ CKD (Frank Uschner)
No patients who had undetectable HDV RNA at 48 weeks off-treatment had relapse at week 96; most relapses happened by 24 weeks off treatment. Posttreatment HBsAg loss happened in 4 patients #EASLCongress
Heiner Wedemeyer now presents 96-week data after end of treatment for bulevirtide in HDV (1ry outcome data at 48 weeks on treatment) #EASLCongress
1-year transplant free survival (1st endpoint) was not sig different - HR0.80 (95% CI 0.58-1.10). OS HR was 0.71 (0.49-1.02). HRS and SBP might be less frequent with albumin. Safety outcomes were broadly similar. #EASLCongress
Javier Fernandez now presents data from the PRECIOSA trial of open label long-term albumin in patients with cirrhosis and ascites (n=200 per group) #EASLCongress
First year as part of the EASL Task Force for Nurses and Allied Health Professionals done! My tasks included lecturing on nutrition in the palliative disease course, chairing a session on multiprofessional treatment of ACLF, and leading a workshop on PROMs and PREMs. So much fun! #EASLcongress
Resmetirom treatment associated with improvements in liver enzyme levels and atherogenic markers. Discontinuations were infrequent; there were 6 decompensation events #EASLCongress
Naim Alkhouri now presents single-arm data for resmetirom in MASH cirrhosis, comprising total ~104 weeks of treatment #EASLCongress
Time to say goodbye to #EASLCongress 2025 in beautiful Amsterdam.
It was a privilege to be part of this year's faculty, and to deepen the collaboration between @easlnews.bsky.social and @escmid.bsky.social @esgvh.bsky.social.
Heading off to share this year's insight with colleagues back home.
A greater proportion of NCA arm improved by>=1 Ludwig stage at week 96; no difference in PROs; AE/SAE profile similar #EASLCongress
Patients without second biopsy were non-responders; 15% in the NCA arm achieved the composite primary endpoint vs 4% in the pbo group #EASLCongress
#EASLCongress wraps up with the late-breakers, and Michael Trauner presenting data from the phase 3 trial of norucholic acid in PSC
👏 Fantastic job by Annarein Kerbert, LUMC, + Julian Pohl, Charité, at today's #networking session at #EASLCongress
👉 Is #alcohol-related #hepatitis in ACLF its own beast?
👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis?
Chair @rajivjalan.bsky.social
